Disability

Oragenics Inc. Completes Spray Dry Drug Manufacturing and Intranasal Device Filling in Anticipation of Phase IIa Clinical Trial in Concussed Patients

• Falls and car accidents lead incidence of concussions in emergency departments • Spray-dried drug formulation allows for easy delivery to patients…

1 year ago

Bioxodes reports positive DMC meeting for BIOX-101 Phase 2a trial in intracerebral hemorrhagic stroke

 Planned Data Monitoring Committee (DMC) meeting recommended continuation of the study after reviewing data from the first 8 patients  Interim data…

1 year ago

ABLE United Marks $100 Million Savings Milestone on Inaugural National ABLE Savings Day

Florida's ABLE program reaches a major milestone, empowering individuals with disabilities and their families to save for future expenses, while…

1 year ago

Enlyte Celebrates National Adjuster Day by Launching Streamlined DecisionPoint Interface

Revised system is designed to empower adjuster decision-making and increase productivity SAN DIEGO, Aug. 16, 2024 /PRNewswire/ -- Adjusters are often…

1 year ago

Remote access, real impacts: Assessing telehealth attitudes and usage in Northwest Colorado

New report identifies benefits and concerns regarding telehealth, provides recommendations for improving perceptions  DENVER, Aug. 14, 2024 /PRNewswire/ -- The Office…

1 year ago

Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range

• ONP-002 stability eliminates need for cumbersome cold storage• No FDA-approved pharmaceutical treatment available for concussion SARASOTA, Fla., Aug. 14,…

1 year ago

Uplifting Military and Disability Communities: The N2 Company Launches Salute & Uniquely You Magazines

IRVING, Texas, Aug. 13, 2024 /PRNewswire/ -- The N2 Company (N2) recently launched two groundbreaking monthly magazines, Salute and Uniquely You,…

1 year ago

Theralase(R) Release’s 2Q2024 Financial Statements

TORONTO, ON / ACCESSWIRE / August 12, 2024 / Theralase® Technologies Inc. ("Theralase®" or the "Company") (TSXV:TLT)(OTCQB:TLTFF), a clinical stage…

1 year ago

Oragenics Inc. Announces Concussion Drug, ONP-002, Successfully Clears FDA-Required Cardiotoxicity Testing

The potential addressable market opportunity for ONP-002 includes an estimated 69 million concussions globallySARASOTA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE)…

1 year ago

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11

MoonLake Immunotherapeutics Reports Second Quarter 2024 Financial Results and Announces a Capital Markets Update for September 11 Initiated Phase 3…

1 year ago